Neuropathix, Inc

Headquarters

Unknown, US

Neuropathix, Inc. is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs. The company's lead candidate is KLS-13019, a patented, non-opioid cannabinoid derivative for neuropathic pain.

• Kannalife Sciences, IncKannalife Sciences, Inc., a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthrough therapeutics targeting inflammation to treat patients with significant unmet medical needs. The company is a pioneer in breakthrough therapeutics targeting neuroinflammation, healthspan and neuropathic pain.DOYLESTOWN, PA
• MAXONA Pharmaceuticals, IncMAXONA Pharmaceuticals is a clinical-stage pharmaceutical company leveraging innovation to develop the next generation of therapies to help patients maximize life. MAXONA's initial focus is on addressing the urgent need for new effective therapies that treat acute and chronic pain, without the side effects and addiction risks associated with NSAIDS and opioids. MAXONA's lead compound, MAX-001 is a non-opioid, non-NSAID oral therapy with a novel mechanism of action that is initially being developed in the U.S. to treat acute and chronic pain.MALVERN, PA
• Baudax BioBaudax Bio is a revenue-generating, specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings. The company has multiple non-opioid therapeutics in clinical development for pain conditions and is currently promoting their lead product, ANJESO™, for management of moderate-to-severe pain.MALVERN, PA
• ST
  SRIN TherapeuticsSRIN Therapeutics is advancing novel treatment options for patients by harnessing the power of the endocannabinoid system. The company focuses on biotechnology and pharmaceuticals.PHILADELPHIA, PA